For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Bcl-2 (B-cell lymphoma 2) is an oncogenic protein that inhibits apoptosis. It is a protein with a MW of 24-26 kDa, located within the mitochondrial membrane, endoplasmic reticulum and nuclear envelope. Bcl-2 is considered an important antiapoptotic protein and is thus classified as a proto-oncogene. Bcl-2 overexpression has been implicated in a wide variety of malignancies including (but not limited to) breast, prostate, skin, colon and pancreatic cancers as well as neurodegenerative and autoimmune diseases. Related anti-apoptotic proteins include Bcl-xL, Mcl-1 and Bcl-w. Proapoptotic proteins in the Bcl-2 family include Bax, BAD, Bak, Blk and Bid.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||100 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.